Skip to main content Back to Top
Advertisement

11/28/2022

Bacteriostatic 0.9% Sodium Chloride Vials

Products Affected - Description

    • 0.9% Sodium Chloride injection, Fresenius Kabi, bacteriostatic 30 mL vial, 25 count, NDC 63323-0924-30
    • 0.9% Sodium Chloride injection, Pfizer, bacteriostatic 10 mL vial, 25 count, NDC 00409-1966-12
    • 0.9% Sodium Chloride injection, Pfizer, bacteriostatic 20 mL vial, 25 count, NDC 00409-1966-05
    • 0.9% Sodium Chloride injection, Pfizer, bacteriostatic 30 mL vial, 25 count, NDC 00409-1966-07

Reason for the Shortage

    • Fresenius Kabi has bacteriostatic sodium chloride on shortage due to increased demand.
    • Pfizer has bacteriostatic sodium chloride on shortage due to increased demand.

Available Products

    • 0.9% Sodium Chloride injection, Fresenius Kabi, bacteriostatic 10 mL vial, 25 count, NDC 63323-0924-10

Estimated Resupply Dates

    • Pfizer has bacteriostatic 0.9% sodium chloride 10 mL and 20 mL vials on back order and the company estimates a release date of March 2023 for the 10 mL vials and December 2022 for the 20 mL vials. The 30 mL vials are available in limited supply.
    • Fresenius Kabi has bacteriostatic 0.9% sodium chloride 30 mL vials on back order and the company estimates a release date of mid- to late-December 2022.

Updated

Updated November 28, 2022 by Michelle Wheeler, PharmD, Drug Information Specialist. Created November 16, 2021 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2022, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.